Toggle navigation
Menu
Home
News
Local
National
World
Politics
Sports
Entertainment
Business
Health
News Tip Hotline
Weather
Bend
Traffic
Live Traffic Cams
Central Oregon
Mountain Passes
Road Reports
Trip Check
Gas Prices
Closures and Delays
Stations
KQAK-FM 105.7
The Peak 104.1
The Ranch 95.7 FM
KBNW-AM/FM
KRCO-AM
Events
Upcoming
Concerts
Submit An Event
Submit A PSA
Interviews
Inside Central Oregon
Central Oregon Spotlight
Water Wise Tips
HBG Interviews
Ray’s Random Questions
Just Used Cars as Heard on KQAK & The Ranch
About MCO
Contact/About Us
Advertise
Careers
Media Kit
Radio Stations
Contest Rules
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Legend Biotech Corporation - American Depositary Shares
(NQ:
LEGN
)
18.57
-0.75 (-3.88%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Legend Biotech Corporation - American Depositary Shares
< Previous
1
2
3
4
5
Next >
Legend Biotech Launches Inaugural ELITE Grant Program to Advance the Next Generation of CAR-T Innovation in Multiple Myeloma
October 01, 2026
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Legend Biotech Presents CARVYKTI Data Showing Half of Patients with RRMM Remained Progression-Free and Alive Five Years After a Single Infusion
September 25, 2026
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Legend Biotech Appoints Ingrid Zhang as Chief Executive Officer
September 15, 2026
Ingrid Zhang, an accomplished global biopharmaceutical leader, joins Legend Biotech following a comprehensive Board-led search process
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Legend Biotech to Present Updated Long-Term and Real-World Evidence from CARVYKTI Clinical Program at the International Myeloma Society Annual Meeting
September 10, 2026
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Legend Biotech to Participate in the Morgan Stanley Global Healthcare Conference
September 01, 2026
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Legend Biotech Reports Second Quarter 2026 Results and Recent Highlights
August 11, 2026
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Legend Biotech to Host Investor Conference Call on Second Quarter 2026 Results
July 28, 2026
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Legend Biotech Announces CEO Transition
July 27, 2026
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Calidi Biotherapeutics Appoints Former Genentech/Roche and Celgene Executive Corsee Sanders, Ph.D., to Board of Directors
June 23, 2026
Industry Veteran Brings More Than Three Decades of Biopharmaceutical Development and Clinical Operations Experience to Help Guide Pipeline Advancement
From
Calidi Biotherapeutics, Inc
Via
GlobeNewswire
Legend Biotech Corporation Announces Pricing of Public Offering
June 17, 2026
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Legend Biotech Corporation Announces Proposed Public Offering
June 17, 2026
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
June 15, 2026
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
June 14, 2026
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Legend Biotech Announces Late-Breaking Oral Presentation at EHA 2026 Showcasing Initial Phase 1 In Vivo CAR-T Data with LB2501 in Non-Hodgkin Lymphoma (NHL)
June 02, 2026
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Legend Biotech Presents First-in-Human LB2102 Results in Solid Tumors and New CARVYKTI® Data in Multiple Myeloma at ASCO 2026
June 01, 2026
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Legend Biotech Announces Presentations at ASCO 2026
May 21, 2026
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Legend Biotech Reports First Quarter 2026 Results and Recent Highlights
May 12, 2026
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Legend Biotech Expands Scientific Advisory Expertise to Inform Future Growth
May 04, 2026
Leading experts across cell therapy, oncology, and immunology will provide strategic input as Legend advances and expands beyond its current portfolio
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Legend Biotech to Host Investor Conference Call on First Quarter 2026 Results
April 28, 2026
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Legend Biotech Reports Fourth Quarter and Full Year 2025 Results and Recent Highlights
March 10, 2026
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Legend Biotech to Host Investor Conference Call on Fourth Quarter and Full Year 2025 Results
February 24, 2026
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Legend Biotech to Present CARVYKTI® Data at 2026 Tandem Meetings Reinforcing Growing Evidence Supporting Earlier Use
January 21, 2026
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Legend Biotech Highlights Recent Business Updates at 44th Annual J.P. Morgan Healthcare Conference
January 12, 2026
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Legend Biotech to Present at the 44th Annual J.P. Morgan Healthcare Conference
December 17, 2025
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Legend Biotech Highlights New CARVYKTI® Data in Multiple Myeloma and First-in-Human Results from Novel CAR-T Platform in Non-Hodgkin Lymphoma at ASH 2025
December 06, 2025
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Legend Biotech Celebrates Official Opening of New State-of-the-Art Cell Therapy Research and Development Facility in Philadelphia
November 13, 2025
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Legend Biotech Reports Third Quarter 2025 Results and Recent Highlights
November 12, 2025
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Legend Biotech Announces 10 Presentations at the 67th American Society of Hematology (ASH) Annual Meeting
November 03, 2025
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Legend Biotech to Host Investor Conference Call on Third Quarter 2025 Results
October 29, 2025
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Legend Biotech to Participate in the Morgan Stanley Global Healthcare Conference
August 26, 2025
From
Legend Biotech USA Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
581446795
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/60.0.3112.113 Safari/537.36
00fbf3724072e3a4c643b60a8db5a8756c4f8c05
1
